ইস্রায়েল - হিব্রু - Ministry of Health

novartis pharma services ag - metformin hydrochloride 500 mg; vildagliptin 50 mg - film coated tablets - metformin - eucreas is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.

ইস্রায়েল - হিব্রু - Ministry of Health

dexcel pharma technologies ltd - valsartan - טבליות מצופות פילם - valsartan 40 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

ইস্রায়েল - হিব্রু - Ministry of Health

dexcel pharma technologies ltd - valsartan - טבליות מצופות פילם - valsartan 80 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

ইস্রায়েল - হিব্রু - Ministry of Health

dexcel pharma technologies ltd - valsartan - טבליות מצופות פילם - valsartan 160 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

ইস্রায়েল - হিব্রু - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - טבליות מצופות פילם - sacubitril/valsartan as sodium salt complex 49/51 mg - valsartan and sacubitril

ইস্রায়েল - হিব্রু - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - טבליות מצופות פילם - sacubitril/valsartan as sodium salt complex 49/51 mg - valsartan and sacubitril

ইস্রায়েল - হিব্রু - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - טבליות מצופות פילם - sacubitril/valsartan as sodium salt complex 49/51 mg - valsartan and sacubitril

ইস্রায়েল - হিব্রু - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - טבליות מצופות פילם - sacubitril/valsartan as sodium salt complex 97/103 mg - valsartan and sacubitril

ইস্রায়েল - হিব্রু - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - טבליות מצופות פילם - sacubitril/valsartan as sodium salt complex 97/103 mg - valsartan and sacubitril

ইস্রায়েল - হিব্রু - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - טבליות מצופות פילם - sacubitril/valsartan as sodium salt complex 97/103 mg - valsartan and sacubitril